Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
More about Open Access at the CrickAuthors list
Dennis Plenker Maximilian Riedel Johannes Brägelmann Marcel A Dammert Rakhee Chauhan Phillip P Knowles Carina Lorenz Marina Keul Mike Bührmann Oliver Pagel Verena Tischler Andreas H Scheel Daniel Schütte Yanrui Song Justina Stark Florian Mrugalla Yannic Alber André Richters Julian Engel Frauke Leenders Johannes M Heuckmann Jürgen Wolf Joachim Diebold Georg Pall Martin Peifer Maarten Aerts Kris Gevaert René P Zahedi Reinhard Buettner Kevan M Shokat Neil McDonald Stefan M Kast Oliver Gautschi Roman K Thomas Martin L Sos Toggle all authors (35)
Abstract
Oncogenic fusion events have been identified in a broad range of tumors. Among them, rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill -rearranged tumors. Using chemical genomics in conjunction with phosphoproteomic analyses in -rearranged cells, we identify the CCDC6-RET mutation and drug-induced mitogen-activated protein kinase pathway reactivation as possible mechanisms by which tumors may escape the activity of RET inhibitors. Our data provide mechanistic insight into the druggability of RET kinase fusions that may be of help for the development of effective therapies targeting such tumors.
Journal details
Journal Science Translational Medicine
Volume 9
Issue number 394
Pages eaah6144
Available online
Publication date
Full text links
Publisher website (DOI) 10.1126/scitranslmed.aah6144
Figshare View on figshare
Europe PubMed Central 28615362
Pubmed 28615362
Keywords
Type of publication